Mucinex® for Treatment of Filamentary Keratitis

• Status: Completed
• Trial end date: 2018-07-01
• Target enrollment: 0
• Participant gender: All

Summary

It is a pilot study aimed to determine if oral Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts Eye and Ear Infirmary
• Treatments: Chlorpheniramine, phenylpropanolamine drug combination; Guaifenesin; Phenylpropanolamine

Criteria

Inclusion Criteria:

• Patients with filamentary keratitis

• 18 years and older

Exclusion Criteria:

• Active ocular surface infection of any type

• Recent ocular surgery (<30 days) history of nephrolithiasis as Mucinex® has been associated in rare cases of development of kidney stones

• Schirmer's test<3mm

• History of hypersensitivity to Mucinex®

• Concurrent eye disease requiring immediate initiation of a new treatment (e.g. topical steroids) restriction for water intake can exacerbate the risk of nephrolithiasis.